The 4 Wall Street analysts covering Shoulder Innovations, Inc. hold a median 12-month price target of $26 — +45.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Shoulder Innovations, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (59): The shares have been drifting up relative to others.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +45.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | UBS | Maintains | Buy | — |
| 10 Aug 2026 | UBS | Maintains | Buy | $27 → $28 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $24 → $26 |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $19 → $25 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 28 July 2026 | UBS | Initiates | Buy | $27 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 8 May 2026 | Piper Sandler | Reiterates | Overweight | $18 → $19 |
| 8 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 11 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Overweight | — |
| 12 Nov 2025 | Piper Sandler | Reiterates | Overweight | — |
| 9 Sept 2025 | BTIG | Reiterates | Buy | — |
| 26 Aug 2025 | Morgan Stanley | Initiates | Overweight | — |
| 25 Aug 2025 | Goldman Sachs | Initiates | Buy | — |
| 25 Aug 2025 | Jefferies | Initiates | Buy | — |
| 25 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 6 Mar 2023 | Wedbush | Downgrade | Underperform | $4.00 |
| 2 Mar 2023 | Canaccord Genuity | Downgrade | Hold | $25 → $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Shoulder Innovations, Inc. returned +37.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 16% of US stocks
Cheaper than 30% of US stocks
Cheaper than 88% of US stocks
Higher than 34% of US stocks
Higher than 76% of US stocks
Higher than 90% of US stocks
Higher than 14% of US stocks
Higher than 98% of US stocks
Higher than 28% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Shoulder Innovations, Inc. has a market value of $394.7M and an enterprise value of $382.9M.
Revenue in the twelve months to 30 June 2026: $60.1M. The latest quarter grew 2.8% year on year.
Net income over the same four quarters: −$35.0M, a −58.3% net margin.
Diluted earnings per share, trailing twelve months: $−1.92.
Free cash flow in the twelve months to 30 June 2026: −$47.1M.
Trailing P/E: 23.4×; forward P/E: −12.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Shoulder Innovations, Inc. employs 56 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Shoulder Innovations, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BlockchAIn Digital Infrastructure said it plans to develop a 50-megawatt data center under a newly executed contract with Nebius. Management expects customer prepayments to cover the equity contribution the company must provide.
Why it matters — The item concerns another company's data center financing and has no stated direct connection to Shoulder Innovations.
Shoulder Innovations announced a limited user release of its next-generation InSet® Go glenoid implant for anatomic shoulder arthroplasty, following completion of its first surgical case.
Why it matters — The release marks the start of a limited commercial rollout for SI's next-generation implant.
Shoulder Innovations, Inc. (SI) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation has been published on Seeking Alpha.
Why it matters — The presentation transcript gives SI watchers insight into the company's positioning and messaging at a major healthcare investment conference.
Shoulder Innovations received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity, and has initiated full commercial launch. This marks the second product introduction on the company's new line of technologies for metal-sensitive patients.
Why it matters — A SI watcher would care because this clearance expands the company's product portfolio and launch activity in a dedicated segment for metal-sensitive patients.
Shoulder Innovations announced an exclusive collaboration with ALM Ortho, a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for severe shoulder deformity and complex revision cases where no adequate solution currently exists.
Why it matters — The partnership expands SI's product pipeline into complex revision shoulder reconstruction, an underserved area that could broaden its market reach.
The 4 Wall Street analysts covering Shoulder Innovations, Inc. have a median 12-month price target of $26, with estimates ranging from $25 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Shoulder Innovations, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shoulder Innovations, Inc. 25 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Shoulder Innovations, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (59 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +45.3% from the last close, and Ticker Nerd's factor model ranks Shoulder Innovations, Inc. 25 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Shoulder Innovations, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $28 over the next 12 months.
Shoulder Innovations, Inc. returned +37.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on shoulder arthroplasty solutions.
The most recent item we track (MarketBeat, 8 Oct 2026): "BlockchAIn Digital Infrastructure Says Nebius Prepayment Funds $800M Data Center Build". BlockchAIn Digital Infrastructure said it plans to develop a 50-megawatt data center under a newly executed contract with Nebius. Management expects customer prepayments to cover the equity contribution the company must provide.
Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on shoulder arthroplasty solutions. Shoulder Innovations designs, develops, manufactures, and distributes implant systems and related surgical tools used in shoulder replacement procedures. Its product portfolio includes advanced total and reverse shoulder arthroplasty systems, tray components, planning software, and enabling instruments that support preoperative planning, implant placement, and procedural efficiency. The company’s InSet Glenoid technology is central to its platform, supporting fixation and stability in shoulder implants while addressing clinical challenges in shoulder reconstruction. Shoulder Innovations serves hospitals, ambulatory surgery centers, surgeons, and orthopedic care teams that rely on specialized devices for shoulder surgery. Headquartered in Grand Rapids, Michigan, Shoulder Innovations focuses exclusively on the shoulder surgical care market, making it a specialized participant in the broader orthopedic medical device industry.
CEO Mr. Robert Ball · 56 employees · United States · https://www.shoulderinnovations.com
